CN113730272A - 一种具有缓解眼部疲劳功效的护眼贴及其制备方法 - Google Patents
一种具有缓解眼部疲劳功效的护眼贴及其制备方法 Download PDFInfo
- Publication number
- CN113730272A CN113730272A CN202111164518.5A CN202111164518A CN113730272A CN 113730272 A CN113730272 A CN 113730272A CN 202111164518 A CN202111164518 A CN 202111164518A CN 113730272 A CN113730272 A CN 113730272A
- Authority
- CN
- China
- Prior art keywords
- eye
- relieving
- fatigue
- eye fatigue
- patch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 70
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 55
- 230000000694 effects Effects 0.000 claims abstract description 37
- 239000000843 powder Substances 0.000 claims abstract description 24
- 235000011187 glycerol Nutrition 0.000 claims abstract description 22
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 21
- -1 glycerol glucoside Chemical class 0.000 claims abstract description 10
- 229960003080 taurine Drugs 0.000 claims abstract description 10
- 229930182478 glucoside Natural products 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 8
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims abstract description 8
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 8
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims abstract description 7
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims abstract description 7
- 244000269722 Thea sinensis Species 0.000 claims abstract description 7
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims abstract description 7
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 7
- 239000003755 preservative agent Substances 0.000 claims abstract description 7
- MQWLIFWNJWLDCI-UHFFFAOYSA-L zinc;carbonate;hydrate Chemical compound O.[Zn+2].[O-]C([O-])=O MQWLIFWNJWLDCI-UHFFFAOYSA-L 0.000 claims abstract description 7
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 6
- 229940101267 panthenol Drugs 0.000 claims abstract description 6
- 235000020957 pantothenol Nutrition 0.000 claims abstract description 6
- 239000011619 pantothenol Substances 0.000 claims abstract description 6
- 230000002335 preservative effect Effects 0.000 claims abstract description 6
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 6
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 6
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000008367 deionised water Substances 0.000 claims abstract description 5
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 5
- 229960005375 lutein Drugs 0.000 claims abstract description 5
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims abstract description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 5
- 229940068968 polysorbate 80 Drugs 0.000 claims abstract description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 5
- 239000002562 thickening agent Substances 0.000 claims abstract description 5
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 5
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 5
- ZGSCRDSBTNQPMS-UJURSFKZSA-N 3-O-Ethylascorbic acid Chemical compound CCOC1=C(O)C(=O)O[C@@H]1[C@@H](O)CO ZGSCRDSBTNQPMS-UJURSFKZSA-N 0.000 claims abstract description 4
- 229940120145 3-o-ethylascorbic acid Drugs 0.000 claims abstract description 4
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims abstract description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 18
- 239000011259 mixed solution Substances 0.000 claims description 16
- 238000001816 cooling Methods 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 10
- 238000007873 sieving Methods 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 6
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 4
- 206010004542 Bezoar Diseases 0.000 claims description 4
- 244000293323 Cosmos caudatus Species 0.000 claims description 4
- 235000005956 Cosmos caudatus Nutrition 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 235000012680 lutein Nutrition 0.000 claims description 4
- 239000001656 lutein Substances 0.000 claims description 4
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 4
- 239000011812 mixed powder Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000004745 nonwoven fabric Substances 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 229940107131 ginseng root Drugs 0.000 claims description 3
- 229940102546 rhodiola crenulata root extract Drugs 0.000 claims description 3
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 229920006037 cross link polymer Polymers 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract description 4
- 229940116229 borneol Drugs 0.000 abstract description 4
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract description 4
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 abstract description 2
- 229940041616 menthol Drugs 0.000 abstract description 2
- 229940042585 tocopherol acetate Drugs 0.000 abstract description 2
- 235000020710 ginseng extract Nutrition 0.000 abstract 1
- 235000008210 xanthophylls Nutrition 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 48
- 208000024891 symptom Diseases 0.000 description 29
- 230000000052 comparative effect Effects 0.000 description 16
- 206010016256 fatigue Diseases 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 238000011156 evaluation Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 206010047571 Visual impairment Diseases 0.000 description 8
- 210000004927 skin cell Anatomy 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 206010013774 Dry eye Diseases 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 239000002537 cosmetic Substances 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 206010023644 Lacrimation increased Diseases 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 6
- 230000004317 lacrimation Effects 0.000 description 6
- 230000035807 sensation Effects 0.000 description 6
- 235000019615 sensations Nutrition 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 5
- 206010015958 Eye pain Diseases 0.000 description 5
- 206010015967 Eye swelling Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000037303 wrinkles Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 4
- 208000009847 Eye Foreign Bodies Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010042674 Swelling Diseases 0.000 description 4
- 102000003425 Tyrosinase Human genes 0.000 description 4
- 108060008724 Tyrosinase Proteins 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000037336 dry skin Effects 0.000 description 4
- 239000003889 eye drop Substances 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 235000017709 saponins Nutrition 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 206010006784 Burning sensation Diseases 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 244000246386 Mentha pulegium Species 0.000 description 3
- 235000016257 Mentha pulegium Nutrition 0.000 description 3
- 235000004357 Mentha x piperita Nutrition 0.000 description 3
- 241000475481 Nebula Species 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- 206010068319 Oropharyngeal pain Diseases 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 229930182494 ginsenoside Natural products 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 235000001050 hortel pimenta Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000002085 irritant Substances 0.000 description 3
- 231100000021 irritant Toxicity 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000005808 skin problem Effects 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- 206010010726 Conjunctival oedema Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- DBLDQZASZZMNSL-QMMMGPOBSA-N L-tyrosinol Natural products OC[C@@H](N)CC1=CC=C(O)C=C1 DBLDQZASZZMNSL-QMMMGPOBSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000004330 tyrosol Nutrition 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 241000197194 Bulla Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- 244000175448 Citrus madurensis Species 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 235000002673 Dioscorea communis Nutrition 0.000 description 1
- 241000544230 Dioscorea communis Species 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000002091 Febrile Seizures Diseases 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- 235000017317 Fortunella Nutrition 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 241000795633 Olea <sea slug> Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000035753 Periorbital contusion Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 201000002154 Pterygium Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000997135 Rhodiola crenulata Species 0.000 description 1
- 244000042430 Rhodiola rosea Species 0.000 description 1
- 235000003713 Rhodiola rosea Nutrition 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 206010048629 Wound secretion Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJRNKVDFDLYUGJ-ZIQFBCGOSA-N alpha-Arbutin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-ZIQFBCGOSA-N 0.000 description 1
- 229940033280 alpha-arbutin Drugs 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Chemical class 0.000 description 1
- 229930002877 anthocyanin Chemical class 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940105847 calamine Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- YTJJRAWFHJBAMT-UHFFFAOYSA-N depside Chemical class OC(=O)CC1=C(O)C=C(O)C=C1OC(=O)C1=CC=C(O)C(O)=C1 YTJJRAWFHJBAMT-UHFFFAOYSA-N 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229940082657 digitalis glycosides Drugs 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 206010016284 febrile convulsion Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 229930003944 flavone Chemical class 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Chemical class O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 229910052864 hemimorphite Inorganic materials 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 description 1
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 description 1
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000004283 retinal dysfunction Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/965—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of inanimate origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种具有缓解眼部疲劳功效的护眼贴及其制备方法,所述缓解眼部疲劳护眼贴包括缓解视疲劳功效成分以及甘油、丁二醇、透明质酸钠、增稠剂、聚山梨醇酯‑80、防腐剂、pH调节剂、护肤功效成分和去离子水,其中缓解视疲劳功效成分包括冰片、碳酸锌氢氧化物、琥珀粉、珍珠粉、人工牛黄、薄荷脑、甘油葡糖苷、甘草酸二钾、牛磺酸。护肤功效成分包括泛醇、3‑邻‑乙基抗坏血酸、生育酚乙酸酯、茶多酚、烟酰胺、叶黄素、大花红景天根提取物、人参根提取物等。本发明提供的具有缓解眼部疲劳功效的护眼贴能同时改善视疲劳和眼周肌肤细胞疲劳的眼部问题,安全性高,应用前景良好。
Description
技术领域
本发明属于日用品、护肤品技术领域,具体涉及一种具有缓解眼部疲劳功效的护眼贴及其制备方法。
背景技术
按照症状分类,眼部疲劳可以分为视疲劳以及眼周肌肤细胞疲劳两大类,视疲劳主要表现为用眼后出现视觉障碍(近距离工作或阅读不持久,出现暂时性视力模糊或重影)、眼部不适(眼胀、眼痛、眼干、眼烧灼感、流泪、眼异物感及眼眶疼痛)等症状,而眼周肌肤细胞疲劳则主要表现为眼周肌肤暗淡、松弛、干燥等问题,进而导致出现黑眼圈、眼袋、鱼尾纹、脂肪粒等眼周肌肤问题。
视疲劳即由于各种病因使得人眼视物时超过其视觉功能所能承载的负荷,导致用眼后出现视觉障碍、眼部不适或伴有全身症状等以至不能正常进行视作业的一组症候群。流行病学研究结果显示,23%学龄儿童、64%~90%电脑使用者及71.3%干眼患者均有不同程度的视疲劳症状。视疲劳常用的治疗手段为药物治疗,例如改善眼调节功能的七叶洋地黄双苷滴眼液以及人工泪液玻璃酸钠滴眼液、羟甲基纤维素钠滴眼液等。
眼周肌肤细胞疲劳是指眼部肌肤的细胞超过其所能承载的负荷而受损,眼部肌肤极易产生细胞疲劳而受损,具体原因如下:1)眼部肌肤人体皮肤最薄的部位,眼部表皮与真皮的厚度只有0.25~0.55mm,因此更容易受到外界的伤害;2)眼部皮下几乎没有皮脂腺与汗腺分布,眼周细薄皮肤非常容易干燥,缺少水分;3)眼周肌肤敏感脆弱,微血管极为微细,同时其中胶原蛋白和弹性纤维分布很少,缺少肌肉支撑,很容易产生皱纹、黑眼圈、眼袋;4)眼睛每天正常工作要眨动1万次,因此眼部肌肤的工作负荷重,易疲劳和衰老。眼周肌肤细胞疲劳常用的改善手段为使用眼霜、眼膜、眼部精华等眼部护理品。
近年来,随着社会环境变化,视频终端普及和工作节奏加快,视觉使用已远超负荷,现代社会同时存在视疲劳和眼周肌肤细胞疲劳问题的人越来越多,而目前市面上缓解眼部疲劳的产品一般为分别针对视疲劳和眼周肌肤细胞疲劳的产品,其功效单一,眼部视觉障碍、眼部不适以及眼周肌肤暗淡、松弛、干燥等眼部问题尚未能统一有效缓解或解决,尤其产品安全性无法保证。
发明内容
针对现有技术存在的不足,本发明的目的在于提出一种具有缓解眼部疲劳功效的护眼贴及其制备方法,不仅能同时改善视疲劳和眼周肌肤细胞疲劳的眼部问题,有效缓解或解决眼部视觉障碍、眼部不适以及眼周肌肤暗淡、松弛、干燥等眼部疲劳症状,还具有较好的安全性,对眼部无刺激。
为了实现上述目的,本发明采用如下技术方案:
一种具有缓解眼部疲劳功效的护眼贴,由以下重量份的原料制成:
在以上技术方案的基础上,优选的,所述缓解视疲劳功效成分由以下重量份的原料制成:
在以上技术方案的基础上,优选的,所述护肤功效成分由以下重量份的原料制成:
在以上技术方案的基础上,优选的,所述增稠剂选自纤维素类物质、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物、聚丙烯酸酯交联聚合物-6、丙烯酸酯类/C10-30烷醇丙烯酸酯类交联共聚物、黄原胶中的一种或多种。
在以上技术方案的基础上,更进一步优选的,所述纤维素类物质为羟乙基纤维素、羧甲基纤维素中的一种或多种。
在以上技术方案的基础上,优选的,所述防腐剂为euxyl PE 9010、Zeastat、Microcare PHDG中的一种或多种。
本发明缓解眼部疲劳护眼贴缓解视疲劳功效成分中的碳酸锌氢氧化物、冰片、人工牛黄、琥珀粉、珍珠粉共奏清热退赤、止痒去翳、改善视疲劳之功效,诸药配伍,能够较好的缓解眼睛红肿痛痒、眼烧灼感和异物感以及流泪等症状,具体功效如下:
碳酸锌氢氧化物:即炉甘石(煅),主要成分具有解毒明目退翳,收湿止痒敛疮。用于目赤肿痛,眼缘赤烂,翳膜胬肉,溃疡不敛,脓水淋漓,湿疮,皮肤瘙痒。现代药理:为不溶于水的天然碳酸锌,广用于皮肤科,作为中度的防腐、收敛、保护剂治疗皮肤炎症或表面创伤;一般用5~10%水混悬液(洗剂),亦有用油膏者;外用可抑制局部葡萄球菌生长;能部分吸收创面分泌液,有收敛、保护作用;上能抑制局部葡萄球菌的生长。
冰片:辛、苦,微寒。归心、脾,肺经。开窍醒神,清热止痛。用于闭证神昏、目赤肿痛、喉痹口疮、疮疡肿痛,溃后不敛等病症。现代药理:冰片局部应用对感觉神经有较微刺激,有一定的止痛及温和的防腐作用。较高浓度(0.5%)对葡萄球菌、链球菌、肺炎双球菌、大肠杆菌及部分致病性皮肤真菌等有抑制作用。
人工牛黄:甘,凉。归心、肝经。清心,豁痰,开窍,凉肝,息风,解毒。用于热病神昏,中风痰迷,惊痫抽搐,癫痫发狂,咽喉肿痛,口舌生伴随,痈肿疔疮。
珍珠粉:甘咸,寒。安神定惊,清热滋阴,明目,解毒。用于热病惊痫、烦热不眠、咽喉肿痛糜烂、口疮、溃疡不收口、目赤翳障、并能润泽肌肤。现代研究还表明珍珠在提高人体免疫力、延缓衰老、祛斑美白、补充钙质等方面都具有独特的作用。
琥珀粉:甘、平。镇静,利尿,活血。用于惊风,癫痫,心悸,失眠,小便不利,尿痛,尿血,闭经。
进一步的,本发明所用薄荷脑由薄荷的叶和茎中所提取,白色晶体,为薄荷和欧薄荷精油中的主要成分。在医药上用作刺激药,作用于皮肤或粘膜,有清凉止痒作用;内服可作为驱风药,用于头痛及鼻、咽、喉炎症等。
进一步的,本发明所用甘草酸二钾为白色或类白色细粉末,有特殊甜味,水溶好、口感纯。甘草酸二钾具有抑菌、消炎、解毒、抗敏、除臭等多种功效。在医药、化妆品日化、食品等行业有广泛的应用。可用于眼药水、口腔炎的药膏。可活化皮质甾类化合物(抑制代谢酶),间接增强皮质甾类化合物的作用,可用于膏、霜、水、乳液、奶类和蜜类等所有化妆品,它可以中和或减低化妆品的有毒物质,也可以防止有的化妆品的过敏反应。
进一步的,本发明所用牛磺酸又称β-氨基乙磺酸,是一种含硫的非蛋白氨基酸,在体内以游离状态存在,不参与体内蛋白的生物合成。婴幼儿如果缺乏牛磺酸,会发生视网膜功能紊乱。长期的静脉营养输液的病人,若输液中没有牛磺酸,会使病人视网膜电流图发生变化,只有补充大剂量的牛磺酸才能纠正这一变化。牛磺酸还具有调节晶体渗透压和抗氧化等重要作用,在白内障发生发展过程中,晶状体中山梨酸含量增加,晶体渗透压增加,而作为调节渗透压的重要物质牛磺酸浓度则明显降低,抗氧化作用减弱,晶体中的蛋白质发生过度氧化,从而引起或加重白内障的发生。补充牛磺酸可抑制白内障的发生发展。
进一步的,本发明所用甘油葡糖苷是一类由甘油分子和葡萄糖分子通过糖苷键连接而形成的糖苷类化合物,由天然螺旋藻通过藻细胞内生物合成技术得到的一种高纯度单一2α分子构型的天然产物。研究发现,甘油葡糖苷能促进天然保湿因子NMF的生成,具有良好的保湿和渗透功能,还能防止紫外线的伤害,同时能降低SCF的浓度达到抗炎效果。
进一步的,本发明缓解眼部疲劳护眼贴中护肤功效原料中使用叶黄素,其作为一种类胡萝卜素,具有极佳的抗氧化剂活性,能过滤对细胞有害的高能蓝光;其吸收光谱特征带为400-500nm之间,恰好落在蓝光区域,对阻隔蓝光也有一定作用。同时,叶黄素还能有效地延缓皮肤弹性蛋白和胶原蛋白的降解,达到增加皮肤弹性的目的。
进一步的,本发明使用的人参根提取物活性成分为人参皂苷。按皂苷元的不同,人参皂苷可分为达玛烷型和齐墩果型皂苷两种。其中根据糖基在苷元上连接位置的不同,达玛烷型皂苷又分为原人参二醇型和原人参三醇型皂苷。其代表分别为Rb1和Rg1,被认为是人参最主要的活性成分。研究表明人参皂苷Rb1、Rg1和Re通过影响成纤维细胞的基因及蛋白质的表达,显著促进胶原蛋白合成、抑制胶原蛋白的降解,从而提高胶原蛋白总量、改善胶原蛋白代谢。同时人参皂苷Rb1能通过抑制黑色素细胞的一氧化氮合成酶活性从而抑制黑色素细胞增殖达到美白效果。
进一步的,本发明使用的大花红景天根提取物活性成分为红景天甙、甙元酪醇、氨基酸以及黄酮类。红景天的大量药理学研究证明红景天苷、酪醇等多酚类成分为抗缺氧、抗缺血、美白、抗辐射、抗衰老的有效成分。体外酪氨酸酶抑制实验表明,大花红景天冻干粉对酪氨酸酶抑制活性约为α-熊果苷的10倍,是酪氨酸酶的高效抑制剂。
进一步的,本发明使用烟酰胺和生育酚乙酸酯。烟酰胺(维生素B3)与生育酚乙酸酯(维生素E)搭配使用可防御表皮层活性氧自由基ROS的产生。同时烟酰胺能减轻和预防皮肤在早期衰老过程中产生的肤色黯淡、发黄、菜色。修复受损的角质层脂质屏障,提高皮肤抵抗力。还具有深层锁水、保湿功效。而生育酚乙酸酯维生素E有较强的还原性,可作为抗氧化剂。作为体内抗氧化剂,消除体内自由基,减少紫外线对人体的伤害。
进一步的,本发明所用的泛醇,即维生素原B5,是应用较广泛的维生素B类营养补充剂,泛醇的分子量较小,能够有效渗透角质层,浸润肌肤表面的角质层,具有强效的保湿效果,有效改善肌肤粗糙,使肌肤柔软,并且不黏腻,同时有助于舒缓皮肤不适、瘙痒,刺激表皮细胞生长。
进一步的,本发明所用的3-邻-乙基抗坏血酸,又称VC乙基醚,是维生素C的迄今最好的衍生物,它不仅在化学结构上稳定,而且是真正意义上的不变色的维生素C的衍生物,而且它在进入皮肤后,和维生素C在体内代谢途径相同,从而发挥更好的维生素C的效果。研究表明,VC乙基醚具有抑制酪氨酸酶活性,有效阻止黑色素的合成,高效祛斑;促进胶原蛋白合成,改善皮肤暗淡无光,赋予皮肤弹性;强力抗氧化,有效去除自由基;抵抗日光引起的炎症,较强的抗菌作用;具有亲水和亲油作用,易于皮肤吸收,直接到达真皮;稳定性良好,耐热,耐酸,耐碱,耐盐以及耐氧化等活性优势。
进一步的,本发明所用的茶多酚,又名抗氧灵、维多酚、防哈灵,是茶叶中所含的一类多羟基类化合物,简称TP,主要化学成分为儿茶素类(黄烷醇类)、黄酮及黄酮醇类、花青素类、酚酸及缩酚酸类、聚合酚类等化合物的复合体。茶多酚能清除面部的油腻,收敛毛孔,具有消毒、灭菌、抗皮肤老化,减少日光中的紫外线辐射对皮肤的损伤等功效。茶多酚能够阻挡紫外线和清除紫外线诱导的自由基,从而保护黑色素细胞的正常功能,抑制黑色素的形成。同时对脂质氧化产生抑制,减轻色素沉着。
本发明还提供一种上述护眼贴的制备方法,包括如下步骤:
(1)将冰片、薄荷脑用聚山梨醇酯-80加热溶解,然后加入生育酚乙酸酯,溶解均匀,得E相混合液,待用;
(2)将琥珀粉、珍珠粉粉碎后与碳酸锌氢氧化物混合,随后研磨、过筛,得混合药粉;接着将所述混合药粉气流粉碎;最后,常温下用甘油将粉碎后的混合药粉分散均匀,得B相混合液,待用;
(3)将增稠剂、透明质酸钠用丁二醇和剩余部分的甘油分散均匀,随后加入泛醇、甘草酸二钾及去离子水并加热溶解,保温搅拌10~20min;接着过筛后加入B相混合液,保温搅拌10~20min后降温;
(4)待步骤(3)中混合物温度降至55℃以下后,加入E相混合液、人工牛黄、甘油葡糖苷、牛磺酸、3-邻-乙基抗坏血酸、茶多酚、烟酰胺、叶黄素、大花红景天根提取物、人参根提取物、防腐剂,用pH调节剂调节pH值,继续降温搅拌直至完全溶解均匀,保证至少搅拌10~30min,搅拌结束后得到缓解眼部疲劳护眼贴精华液;
(5)将步骤(4)所得缓解眼部疲劳护眼贴精华液用无纺布装袋,即得缓解眼部疲劳护眼贴。
在以上技术方案的基础上,优选的,步骤(4)中所述pH调节剂选自柠檬酸、氨甲基丙醇中的一种或多种。
在以上技术方案的基础上,优选的,步骤(4)中调节pH值后,所得缓解眼部疲劳护眼贴精华液稀释至10%wt的溶液pH值为5.5~7.5。
在以上技术方案的基础上,优选的,步骤(2)和步骤(3)中甘油用量比为0.2~3:1。
在以上技术方案的基础上,优选的,步骤(3)中加热溶解温度为70~90℃。
与现有技术相比,本发明具有以下有益效果:
(1)本发明的护眼贴安全无刺激,不仅能有效缓解视觉障碍、眼胀、眼痛、眼干、眼烧灼感、流泪、眼异物感等视疲劳症状,同时还有助于改善眼周皮肤暗沉、眼周皮肤干燥、眼部皱纹、黑眼圈等眼周肌肤问题,总有效率达到100%,且试用前后的症状总积分检验结果显示有统计学意义。
(2)本发明护眼贴中的VC乙基醚是亲水亲油的两性物质,这种两性物质能很快的透过角质层并到达真皮,从而发挥生物学功效,因此可以协同其他成分更好地进入皮肤。甘油葡糖苷由于具有重要生理功能结构2-α构型,其不仅具有较好的保湿、抗炎、抗过敏等性能,还有助于稳定本发明护眼贴中的其他大分子,从而进一步提升缓解眼部疲劳的效果。此外,本发明实验表明,VC乙基醚与甘油葡萄糖苷在护眼贴中表现出了较好的协同作用,进一步提升了产品改善视疲劳和眼周肌肤细胞疲劳的性能。
具体实施方式
下面将结合本发明实施方式,对本发明实施方式中的技术方案进行清楚、完整地描述,显然,所描述的实施方式仅仅是本发明一部分实施方式,而不是全部的实施方式。基于本发明中的实施方式,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施方式,都属于本发明保护的范围。
需要特别说明的是,本发明中使用的甘油葡糖苷购自青岛中科蓝智生物科技发展有限公司。
实施例1
一种具有缓解眼部疲劳功效的护眼贴,以总料量100g计,由以下原料制备得到:
本实施例中,还提供一种上述护眼贴的制备方法,包括如下步骤:
(1)将冰片、薄荷脑用聚山梨醇酯-80加热溶解,然后加入生育酚乙酸酯,溶解均匀,得E相混合液,待用;
(2)将琥珀粉、珍珠粉粉碎,过100目筛后与碳酸锌氢氧化物混合,随后研磨、过160目筛,得混合药粉;接着将所述混合药粉气流粉碎至200目;最后,常温下用甘油将粉碎后的混合药粉分散均匀,得B相混合液,待用;
(3)将A相中的羟乙基纤维素、透明质酸钠用丁二醇和甘油分散均匀,随后加入泛醇、甘草酸二钾及去离子水并于80℃下加热溶解,保温搅拌15min;接着过150目筛后加入B相混合液,保温搅拌15min后降温;
(4)待步骤(3)中混合物温度降至55℃以下后,依次加入C相各物质、D相各物质,降温搅拌20min,随后加入E相混合液、防腐剂,用柠檬酸调节体系pH值,继续降温搅拌20min直至完全溶解均匀,搅拌结束后得到缓解眼部疲劳护眼贴精华液;
(5)将步骤(4)所得缓解眼部疲劳护眼贴精华液用无纺布装袋,即得缓解眼部疲劳护眼贴。
其中,用柠檬酸调节pH时,所得缓解眼部疲劳护眼贴精华液稀释至10%wt的溶液pH值为6.5即可。
实施例2
一种具有缓解眼部疲劳功效的护眼贴,以总料量100g计,由以下原料制备得到:
本实施例中,还提供一种上述护眼贴的制备方法,包括如下步骤:
(1)将冰片、薄荷脑用聚山梨醇酯-80加热溶解,然后加入生育酚乙酸酯,溶解均匀,得E相混合液,待用;
(2)将琥珀粉、珍珠粉粉碎,过100目筛后与碳酸锌氢氧化物混合,随后研磨、过160目筛,得混合药粉;接着将所述混合药粉气流粉碎至200目;最后,常温下用甘油将粉碎后的混合药粉分散均匀,得B相混合液,待用;
(3)将A相中的羟乙基纤维素、透明质酸钠用丁二醇和甘油分散均匀,随后加入泛醇、甘草酸二钾及去离子水并于85℃下加热溶解,保温搅拌10min;接着过150目筛后加入B相混合液,保温搅拌10min后降温;
(4)待步骤(3)中混合物温度降至55℃以下后,依次加入C相各物质、D相各物质,降温搅拌10min,随后加入E相混合液、防腐剂,用柠檬酸调节体系pH值,继续降温搅拌15min直至完全溶解均匀,搅拌结束后得到缓解眼部疲劳护眼贴精华液;
(5)将步骤(4)所得缓解眼部疲劳护眼贴精华液用无纺布装袋,即得缓解眼部疲劳护眼贴。
其中,用柠檬酸调节pH时,所得缓解眼部疲劳护眼贴精华液稀释至10%wt的溶液pH值为6.0即可。
实施例3~4
实施例3~4中,一种具有缓解眼部疲劳功效的护眼贴,以总料量100g计,制备原料配比见下表所示:
实施例3与实施例4的制备方法同实施例1,不同之处在于各物质用量、防腐剂种类及体系的pH调节值和调节剂有所差异。
对比例1~2
对比例1~2中,一种具有缓解眼部疲劳功效的护眼贴,以总料量100g计,制备原料配比见下表所示:
对比例1与对比例2的制备方法同实施例1,不同之处在于物质的组成略有差异。
分别对实施例1~4以及对比例1~2所制备的护眼贴进行产品测试评价,包括皮肤刺激性测试、缓解眼部疲劳功效评价,具体方法如下:
一、皮肤刺激性测试
测试过程:受试者共计30人,具体性别构成和年龄构成随机确定,且均符合《化妆品接触性皮炎诊断标准及处理原则》纳入、排除标准。
选用合格斑贴材料,将实施例1制得样品放入斑试器内,样品用量为0.2g,对照孔不置任何物质作为空白。将样品和空白对照均贴于受试者的前臂曲侧,用手掌轻压使之均匀贴敷于皮肤上,持续24h。去除斑贴器后间隔30min,待压痕消失后观察皮肤反应。斑贴试验后24h和48h分别再观察一次,观察皮肤反应。
判定标准:根据《化妆品接触性皮炎诊断标准及处理原则》分类判定:受试部位无反应为(0),皮肤出现淡红斑为(1),皮肤出现红斑、浸润或丘疹为(2),皮肤出现水肿性红斑、丘疹为(3),皮肤出现显著红肿、伴丘疹或大疱为(4)。
30例中出现2级皮肤不良反应的人数多于2例,或出现任何1例3级或3级以上皮肤不良反应时,判定受试物对人体有不良反应。
皮肤刺激性测试得到的去除斑试器0.5h的结果见表1。
表1
试验结果表明:此次试验中斑贴试验结果,根据2015《化妆品卫生规范》的要求,判定本发明的缓解眼部疲劳护眼贴对人体皮肤无不良反应。
二、缓解眼部疲劳功效评价
对实施例1~4及对比例1~2的护眼贴进行缓解视疲劳以及改善眼周肌肤效果进行临床试用评价。
试验方法:随机选取180名每天面对着LED屏幕过度用眼,存在视觉障碍、眼胀、眼痛、眼干、眼烧灼感、流泪、眼异物感等视疲劳症状,且同时存在眼周肌肤暗淡、干燥,存在黑眼圈、眼部皱纹等问题的志愿者,年龄为20-50岁。随机分成6组,每组30人,第1-4组分别使用实施例1-4制备的护眼贴,第5-6组分别使用对比例1-2制备的护眼贴,志愿者每天晚上使用1次,每次使用10-15分钟,连续使用2周,要求每组志愿者在使用前后填写试用评价表。
通过视觉障碍、眼胀、眼痛、眼干、眼烧灼感、流泪、眼异物感7个症状视疲劳改善效果,其中,无症状为0分,症状轻微为1分,症状明显为2分,症状严重且频繁为3分,并分别计算使用前后7个症状的总积分。
通过眼周皮肤暗沉、眼周皮肤干燥、眼部皱纹、黑眼圈4个症状评价眼部肌肤疲劳改善效果,其中,无症状为0分,症状轻微为1分,症状明显为2分,症状严重为3分,并分别计算使用前后4个症状的总积分。
评价方法:视疲劳和眼部肌肤疲劳通过症状积分减少率进行评价,其中,症状积分减少率=【(使用前总积分-使用后总积分)/使用前总积分】*100%,具体的评价标准为:
显效:症状明显改善,症状积分减少率为60-100%(包括60%);
有效:症状得到一定程度缓解,症状积分减少率为30-60%(包括30%,不包括60%);
无效:症状无明显变化,症状积分减少率小于30%。
实施例1-4及对比例1-2的缓解眼部疲劳护眼贴具体测试结果如下表所示,其中,表2和表3分别为缓解视疲劳的功效评价结果以及总积分分析,表4和表5分别为改善眼周肌肤疲劳的功效评价结果以及总积分分析。
表2缓解视疲劳功效评价结果
组别 | 显效人数 | 有效人数 | 无效人数 | 总有效率 |
实施例1 | 18 | 12 | 0 | 100% |
实施例2 | 16 | 14 | 0 | 100% |
实施例3 | 14 | 16 | 0 | 100% |
实施例4 | 15 | 15 | 0 | 100% |
对比例1 | 12 | 16 | 2 | 93.3% |
对比例2 | 13 | 15 | 2 | 93.3% |
表3缓解视疲劳的总积分分析
组别 | 使用前总积分 | 使用后总积分 |
实施例1 | 10.37±2.341 | 3.87±1.833** |
实施例2 | 10.73±2.196 | 4.17±1.683** |
实施例3 | 11.03±2.173 | 4.53±1.479** |
实施例4 | 11.70±2.184 | 4.50±1.432** |
对比例1 | 10.8±2.265 | 4.97±1.847** |
对比例2 | 10.9±2.187 | 5.03±1.712** |
与使用前比较,*P<0.05,**P<0.01。
表4改善眼周肌肤疲劳功效评价结果
组别 | 显效人数 | 有效人数 | 无效人数 | 总有效率 |
实施例1 | 16 | 14 | 0 | 100% |
实施例2 | 15 | 15 | 0 | 100% |
实施例3 | 12 | 18 | 0 | 100% |
实施例4 | 14 | 16 | 0 | 100% |
对比例1 | 10 | 17 | 3 | 90% |
对比例2 | 12 | 17 | 2 | 93.3% |
表5改善眼周肌肤疲劳的总积分分析
组别 | 使用前总积分 | 使用后总积分 |
实施例1 | 7.97±1.956 | 3.5±1.548** |
实施例2 | 8.2±2.074 | 3.73±1.596** |
实施例3 | 8.13±1.907 | 3.73±1.461** |
实施例4 | 7.77±1.870 | 3.57±1.524** |
对比例1 | 8.03±1.903 | 4.17±1.621** |
对比例2 | 8.13±2.013 | 4.0±1.531** |
与使用前比较,*P<0.05,**P<0.01。
临床试用结果分析可知,本发明制备的缓解眼部疲劳护眼贴安全无刺激,不仅能有效缓解视觉障碍、眼胀、眼痛、眼干、眼烧灼感、流泪、眼异物感等视疲劳症状,同时还有助于改善眼周皮肤暗沉、眼周皮肤干燥、眼部皱纹、黑眼圈等眼周肌肤问题,实施例制得的产品试用两周后的总有效率达到100%,且试用前后的症状总积分检验结果显示有统计学意义。
综上所述,本发明提供的具有缓解眼部疲劳护眼贴,不仅具有缓解用眼过度引起的视疲劳的功效,同时还具有改善眼周肌肤问题的功效。
需要说明的是,本发明通过上述实施例来说明本发明的具有缓解眼部疲劳护眼贴及其制备方法,但本发明并不局限于上述实施例,即不意味着本发明必须依赖上述实施例才能实施。所属技术领域的技术人员应该明了,对本发明的任何改进,对本发明产品和原料的等效替换及辅助成分的添加、具体方式的选择等,均落在本发明的保护范围和公开范围之内。
Claims (10)
4.根据权利要求3所述的一种具有缓解眼部疲劳功效的护眼贴,其特征在于,所述增稠剂选自纤维素类物质、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物、聚丙烯酸酯交联聚合物-6、丙烯酸酯类/C10-30烷醇丙烯酸酯类交联共聚物、黄原胶中的一种或多种。
5.根据权利要求4所述的一种具有缓解眼部疲劳功效的护眼贴,其特征在于,所述纤维素类物质为羟乙基纤维素、羧甲基纤维素中的一种或多种。
6.根据权利要求1~5任一项所述护眼贴的制备方法,其特征在于,包括如下步骤:
(1)将冰片、薄荷脑用聚山梨醇酯-80加热溶解,然后加入生育酚乙酸酯,溶解均匀,得E相混合液,待用;
(2)将琥珀粉、珍珠粉粉碎后与碳酸锌氢氧化物混合,随后研磨、过筛,得混合药粉;接着将所述混合药粉气流粉碎;最后,常温下用甘油将粉碎后的混合药粉分散均匀,得B相混合液,待用;
(3)将增稠剂、透明质酸钠用丁二醇和剩余部分的甘油分散均匀,随后加入泛醇、甘草酸二钾及去离子水并加热溶解,保温搅拌10~20min;接着过筛后加入B相混合液,保温搅拌10~20min后降温;
(4)待步骤(3)中混合物温度降至55℃以下后,加入E相混合液、人工牛黄、甘油葡糖苷、牛磺酸、3-邻-乙基抗坏血酸、茶多酚、烟酰胺、叶黄素、大花红景天根提取物、人参根提取物、防腐剂,用pH调节剂调节pH值,继续降温搅拌直至完全溶解均匀,保证至少搅拌10~30min,搅拌结束后得到缓解眼部疲劳护眼贴精华液;
(5)将步骤(4)所得缓解眼部疲劳护眼贴精华液用无纺布装袋,即得缓解眼部疲劳护眼贴。
7.根据权利要求6所述的制备方法,其特征在于,步骤(4)中所述pH调节剂选自柠檬酸、氨甲基丙醇中的一种或多种。
8.根据权利要求6所述的制备方法,其特征在于,步骤(4)中调节pH值后,所得缓解眼部疲劳护眼贴精华液稀释至10%wt的溶液pH值为5.5~7.5。
9.根据权利要求6所述的制备方法,其特征在于,步骤(2)和步骤(3)中甘油用量比为0.2~3:1。
10.根据权利要求6所述的制备方法,其特征在于,步骤(3)中加热溶解温度为70~90℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111164518.5A CN113730272B (zh) | 2021-09-30 | 2021-09-30 | 一种具有缓解眼部疲劳功效的护眼贴及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111164518.5A CN113730272B (zh) | 2021-09-30 | 2021-09-30 | 一种具有缓解眼部疲劳功效的护眼贴及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113730272A true CN113730272A (zh) | 2021-12-03 |
CN113730272B CN113730272B (zh) | 2024-02-09 |
Family
ID=78725947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111164518.5A Active CN113730272B (zh) | 2021-09-30 | 2021-09-30 | 一种具有缓解眼部疲劳功效的护眼贴及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113730272B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115282168A (zh) * | 2022-08-30 | 2022-11-04 | 马应龙大健康有限公司 | 一种缓解婴幼儿湿疹症状的舒缓润肤霜及其制备方法和应用 |
US20240009262A1 (en) * | 2022-07-09 | 2024-01-11 | Uab Orbio World | Cleansing pad and composition for reducing toxins |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107412258A (zh) * | 2017-08-31 | 2017-12-01 | 陕西理工大学 | 一种具有缓解视疲劳功能的保健眼贴 |
CN112190665A (zh) * | 2020-11-18 | 2021-01-08 | 郑州市新视明科技工程有限公司 | 用于缓解视疲劳的眼贴及其制备方法 |
-
2021
- 2021-09-30 CN CN202111164518.5A patent/CN113730272B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107412258A (zh) * | 2017-08-31 | 2017-12-01 | 陕西理工大学 | 一种具有缓解视疲劳功能的保健眼贴 |
CN112190665A (zh) * | 2020-11-18 | 2021-01-08 | 郑州市新视明科技工程有限公司 | 用于缓解视疲劳的眼贴及其制备方法 |
Non-Patent Citations (2)
Title |
---|
湖北马应龙八宝生物科技有限公司: "瞳话凝时光润萃雨林眼膜贴 备案编号 鄂G妆网备字2019003322", pages 1 - 3, Retrieved from the Internet <URL:https://hzpba.nmpa.gov.cn/gccx/chakanHis.html?prodId=201910281516327seur&gb=G> * |
湖北马应龙八宝生物科技有限公司: "瞳话凝时光润萃雪域眼膜贴 备案编号 鄂G妆网备字2019001801", pages 1 - 3, Retrieved from the Internet <URL:https://hzpba.nmpa.gov.cn/gccx/chakanHis.html?prodId=20190722110027fn1q5&gb=G> * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240009262A1 (en) * | 2022-07-09 | 2024-01-11 | Uab Orbio World | Cleansing pad and composition for reducing toxins |
CN115282168A (zh) * | 2022-08-30 | 2022-11-04 | 马应龙大健康有限公司 | 一种缓解婴幼儿湿疹症状的舒缓润肤霜及其制备方法和应用 |
CN115282168B (zh) * | 2022-08-30 | 2024-05-31 | 马应龙大健康有限公司 | 一种缓解婴幼儿湿疹症状的舒缓润肤霜及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113730272B (zh) | 2024-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109966186B (zh) | 一种含矿物温泉的舒缓保湿修护组合物 | |
CN113730272B (zh) | 一种具有缓解眼部疲劳功效的护眼贴及其制备方法 | |
CN110859791B (zh) | 美白肌肤组合物及其应用、美白肌肤面膜 | |
CN109771348B (zh) | 富含天然产物提取成分的美白保湿除皱面霜及其制备方法 | |
CN108653129B (zh) | 一种包含天然植物抗敏组合物的皮肤敷料 | |
KR20200113600A (ko) | 탈모 및 두피 관리용 조성물 | |
CN109044941B (zh) | 一种皮肤紧致滋养保湿组合物及其制备方法和应用 | |
KR102142426B1 (ko) | 피부 미백 개선 및 진정 효과를 갖는 화장료 조성물, 이를 이용한 화장료 및 이의 제조방법 | |
KR20210104456A (ko) | 피부 항산화 및 피부 진정 효과가 있는 화장료 조성물, 이를 이용한 화장료 및 이의 제조방법 | |
CN111973481A (zh) | 一种蓝酮肽修护精华及其制备方法 | |
CN112472653A (zh) | 一种祛痘芦荟胶及其制备方法 | |
CN110302091B (zh) | 一种含烟酰胺腺嘌呤二核苷酸的抗皮肤衰老组合物及其制备方法和用途 | |
CN106620639A (zh) | 一种补充眼营养抗皱的叶黄素复方植物眼贴 | |
DE202006019184U1 (de) | Feuchtigkeitsspendendes Sanddorn-Hautpflegegel | |
KR102160978B1 (ko) | 피부 트러블 캐어 및 진정 효과를 갖는 화장료 조성물, 이를 이용한 화장료 및 이의 제조방법 | |
KR102190166B1 (ko) | 아토피성 피부염 개선제 조성물, 아토피 피부염 개선제 및 이의 제조방법 | |
CN112472629A (zh) | 一种高良姜草果防晒乳液及其制备方法 | |
CN111700847B (zh) | 协同激光治疗黑眼圈的组合物及眼部精华和制备方法 | |
EP2086554A2 (en) | Methods and compositions for treatment of skin conditions | |
CN114587767A (zh) | 一种冷敷罩、眼部冷敷眼贴及其制备工艺 | |
CN109602653B (zh) | 具有美白功效的组合物、化妆品、精华液及其制备方法 | |
CN112716838A (zh) | 一种玫瑰精油修复紧致眼部精华液及其制备方法 | |
KR101842596B1 (ko) | 삼 추출물을 포함하는 피부 주름 개선용 화장료 조성물 | |
CN115844784B (zh) | 一种用于干燥皮肤舒敏抗炎的组合物及其应用和制备方法 | |
KR102506318B1 (ko) | 소리쟁이를 함유한 지루성두피염 및 탈모완화용 샴푸 제조방법 및 그에 의해 제조된 소리쟁이를 함유한 지루성두피염 및 탈모완화용 샴푸 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: No. 100 Zhoujiawan, Hongshan District, Wuhan City, Hubei Province, 430000 Applicant after: Hubei Mayinglong Biotechnology Co.,Ltd. Address before: 430064 No. 100, Zhoujiawan, Shizishan street, Hongshan District, Wuhan City, Hubei Province Applicant before: HUBEI MAYINGLONG BABAO BIOTECHNOLOGY CO.,LTD. |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |